Having made a name for itself during the health crisis with its ultra-rapid tests, the French start-up, currently in the midst of raising funds, is aiming to become a benchmark in in vitro diagnostics.
The company bases its expertise on spectroscopy combined with Artificial Intelligence (AI). Spectral analysis enables the detection, classification and quantification of samples, and the processing of this complex data (in record time, to determine the status of a sample, or quantify a molecule of interest) is made possible by AI, thanks to the work of the company's data scientists. " The combination of spectroscopy and AI is an innovative method of analysis, the effectiveness of which has been demonstrated by major groups who use our solutions. "emphasizes CEO Roland Carbonnel. The aim of this medical platform is to provide biologists and clinicians with results on the infectious status of their patients - up to 3 pathogens, bacteria and viruses, simultaneously - in less than 3 minutes.
The same automated device is used in veterinary diagnostics for continuous monitoring of the absence or presence of pathogens in farm animals; and in wastewater and bathing water diagnostics for monitoring the evolution of any contamination;". these are real public health issues to which we can provide answers "explains Roland Carbonnel, " I'm thinking in particular of bathing water with the upcoming 2024 Olympics in Paris, where several swimming events will take place in the Seine and Marne rivers ". Especially since GreenTropism's Inno4diag project for water monitoring at whitewater swimming competition sites (Seine and Bassin de la Villette) has been selected by the BPI and the Île-de-France Region.
Thanks in particular to prestigious partnerships with APHP, Irba (Institut de Recherche Biomédicale des Armées), TLL Singapore, the University of Lisbon, Biogroup, Hôpital St Joseph, etc., the company has been able to accelerate its development, with its sights now set on international sales and, even more importantly, a leading position in in-vitro diagnostics.
Since its creation, the company has filed 22 patents - in 5 different families - to protect and secure its operating monopoly and its "unique" technology, from which its ultra-fast diagnostic platform is derived; "to To date, no other technology combines the analytical performance, sample type flexibility, speed and practicality of tests such as those offered by GreenTropism: results are delivered on the spot, in less than 3 minutes, making it possible to carry out large-scale tests at airports, for example. "adds Anthony Boulanger, CTO and founder of the company.
At the same time, GreenTropism has just obtained LNE - Artificial Intelligence certification, becoming the first company in the diagnostics field to have its AI certified: " Over and above our expertise, it's our know-how and exemplary nature that we wanted to be recognized for: AI designed, developed and used with mastery and transparency. "As Roland Carbonnel, CEO, points out, regulations in this area - until now virtually non-existent - are set to flourish in the near future. It was therefore with full knowledge of the facts that the company voluntarily underwent the certification audit, in order to open the doors to the US, 40% of the world market for infectious disease diagnostics, with a market estimated at over 30 billion euros.
These guarantees of reliability are much appreciated by French and international investors in the company, which is currently in the midst of raising Series A capital.